ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "macrophage activation syndrome"

  • Abstract Number: 1149 • ACR Convergence 2020

    Risk Score of Macrophage Activation Syndrome (MAS) in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA)

    Simone Carbogno1, Denise Pires Marafon2, Giulia Marucci2, Emanuela Sacco2, Manuela Pardeo2, Alhanouf Alsaleem3, Sarka Fingerhutova4, Ferhat Demir5, Nastasia Cekada6, Mikhail Kostik7, Christoph Kessel8, Olga Vougiouka9, Alenka Gagro10, Jessica Tibaldi11, Francesca Minoia12, Ilaria Maccora13, Rayfel Schneider14, Pavla Dolezalova15, Betul Sozeri16, Marija Jelusic6, Antonella Insalaco2, Fabrizio De Benedetti17 and Claudia Bracaglia2, 1Pediatric Area, University of Milan, Milan, Italy, 2Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 3Division of Pediatric Rheumatology, Department of pediatrics, King Faisal specialist hospital and research center, Riyadh, Saudi Arabia, RiYADH, Saudi Arabia, 4Rheumatology Unit, Department of Paediatrics and Adolescent Medicine, Charles University in Prague, Dlouha 534, Kladno, 27201, Czech Republic, 5University of Health Sciences, Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology, Istanbul, Turkey, Istanbul, Turkey, 6University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia, Zagreb, Grad Zagreb, Croatia, 7Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, Sto arrivando!, Russia, 8Department of Pediatric Rheumatology and Immunology, University Hospital Muenster, Muenster, Germany, Muenster, Germany, 9Second Department of Paediatrics, P. & A. Kyriakou Children’s Hospital, Athens, Greece, Athens, Greece, 10Children's Hospital Zagreb, Josip Juraj Strossmayer University of Osijek, Medical Faculty Osijek, Zagreb, Croatia, Zagreb, Grad Zagreb, Croatia, 11UOC Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Italy, 12Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, 13Paediatric Rheumatology Unit, Anna Meyer Children's University Hospital, School of Human Health Science, Florence, Italy, Florence, Italy, 14University of Toronto, The Hospital for Sick Children, Toronto, Canada, 15Paediatric Rheumatology and Autoinflammatory Diseases Unit, General University Hospital, Prague, Czech Republic, Prague, Czech Republic, 16University of Health Sciences, Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology Istanbul, Turkey, Istanbul, Turkey, 17Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy

    Background/Purpose: Macrophage Activation Syndrome (MAS) is a severe, life-threatening, complication of Systemic Juvenile Idiopathic Arthritis (sJIA) with a significant mortality. A score that identify sJIA…
  • Abstract Number: 1150 • ACR Convergence 2020

    Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis

    Arianna De Matteis1, Denise Pires Marafon1, Ivan Caiello1, Manuela Pardeo1, Giulia Marucci1, Emanuela Sacco1, Giusi Prencipe1, Fabrizio De Benedetti2 and Claudia Bracaglia1, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 2Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy

    Background/Purpose: Macrophage Activation Syndrome (MAS) and secondary Hemophagocytic Lymphohistiocytosis (sHLH) are hyperinflammatory conditions caused by a cytokine storm, in which IFNγ plays a pivotal role.…
  • Abstract Number: 1151 • ACR Convergence 2020

    Implementation and Initial Experience with a Screening Protocol for Inflammatory Hyperferritinemia

    Michael Zhang1, Corinne Schneider2, Vinh Dang2 and Scott Canna3, 1Children's Hospital UPMC, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, 3University of PIttsburgh, Pittsburgh, PA

    Background/Purpose: Macrophage activation syndrome (MAS) and hemophagocytic lymphohistiocytosis (HLH) epitomize a diverse and deadly group of inflammatory hyperferritinemic syndromes. Early biomarkers distinguishing these syndromes, especially…
  • Abstract Number: 019 • 2020 Pediatric Rheumatology Symposium

    Characterization of DOCK8 as a Novel Gene Associated with Cytokine Storm Syndrome

    Mingce Zhang 1, Remy Cron 1, Devin Absher 2, Prescott Atkinson 1, W. Winn Chatham 1 and Randy Cron1, 1University of Alabama at Birmingham, Birmingham, 2HudsonAlpha Institute for Biotechnology, Huntsville

    Background/Purpose: Cytokine storm syndromes (CSS), such as macrophage activation syndrome (MAS) and secondary hemophagocytic lymphohistiocytosis (HLH), are life threatening conditions that commonly present with unremitting…
  • Abstract Number: 079 • 2020 Pediatric Rheumatology Symposium

    Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis

    Arianna De Matteis 1, Denise Pires Marafon 2, Ivan Caiello 2, Manuela Pardeo 2, Giulia Marucci 2, Emanuela Sacco 2, Giusi Prencipe 2, Fabrizio De Benedetti 2 and Claudia Bracaglia2, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Lazio, Italy, 2Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy

    Background/Purpose: Macrophage Activation Syndrome (MAS) and Secondary Hemophagocytic Lymphohistiocytosis (sHLH) are hyperinflammatory conditions caused by a cytokine storm. Prompt recognition and early treatment are essential…
  • Abstract Number: 080 • 2020 Pediatric Rheumatology Symposium

    Therapeutic Interferon Gamma Neutralization with Emapalumab in Patients with NRLC4- and CDC42-Associated Diseases Characterized by Recurrent and Severe Hemophagocytic Lymphohistiocytosis

    Claudia Bracaglia1, Antonella Insalaco 1, Giulia Marucci 1, Manuela Pardeo 1, Emanuela Sacco 1, Virginia Messia 1, Giusi Prencipe 1, Ivan Caiello 1, Sarka Fingerhutova 2, Pavla Dolezalova 2, Veronica Asnaghi 3, Maria Ballabio 3, Cristina de Min 3 and Fabrizio De Benedetti 1, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 2Paediatric Rheumatology and Autoinflammatory Diseases Unit, General University Hospital, Prague, Czech Republic, 3Swedish Orphan Biovitrum AG (Sobi), Basel, Switzerland

    Background/Purpose: Interferon gamma (IFNγ) is a pivotal mediator of HLH. Emapalumab (a fully human anti-IFNγ monoclonal antibody) is efficacious in patients with primary HLH. In…
  • Abstract Number: 081 • 2020 Pediatric Rheumatology Symposium

    Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis

    Simone Carbogno 1, Denise Pires Marafon 2, Giulia Marucci 2, Manuela Pardeo 2, Antonella Insalaco 2, Virginia Messia 2, Emanuela Sacco 2, Ferhat Demir 3, Betul Sozeri 3, Natasia Cekada 4, Marija Jelusic 4, Olga Vougiouka 5, Mikhail Kostik 6, Alenka Gagro 7, Christoph Kessel 8, Francesca Minoia 9, Fabrizio De Benedetti 2 and Claudia Bracaglia2, 1Pediatric Area, University of Milan, Milan, Italy, 2Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 3University of Health Sciences, Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology, Istanbul, Turkey, 4Division of Paediatric Rheumatology and Immunology, University of Zagreb, Zagreb, Croatia, 5Second Department of Paediatrics, P. & A. Kyriakou Children’s Hospital, Athens, Greece, 6Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, 7Children's Hospital Zagreb, Zagreb, Croatia, 8University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany, 9Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy

    Background/Purpose: Macrophage Activation Syndrome (MAS) is a severe, life-threatening, complication of rheumatic diseases in childhood, particularly of systemic Juvenile Idiopathic Arthritis (sJIA), occurring in approximately…
  • Abstract Number: 108 • 2020 Pediatric Rheumatology Symposium

    A Multinational Study of Thrombotic Microangiopathy in Macrophage Activation Syndrome: A Dreadful Condition Which Is Likely Underrecognized

    Francesca Minoia1, Jessica Tibaldi 2, Valentina Muratore 3, Romina Gallizzi 4, Claudia Bracaglia 5, Alessia Arduini 6, Elif Comak 7, Olga Vougiouka 8, Ralf Trauzeddel 9, Giovanni Filocamo 10, Concetta Micalizzi 2, Ozgur Kasapcopur 11, Erbil Unsal 12, Toshiyuki Kitoh 13, Elena Tsitsamis 14, Mikhail Kostik 15, Randy Cron 16, Jana Pachlopnik 17, Despoina Maritsi 18, Marija Jelusic 19, Susan Shenoi 20 and Angelo Ravelli 2, 1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, 2Istituto Giannina Gaslini, Genoa, Italy, 3IRCCS Policlinico San Matteo, Pavia, Italy, 4Università degli Studi di Messina, Messina, Italy, 5Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 6IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 7Akdeniz University, Antalya, Turkey, 8Second Department of Paediatrics, P. & A. Kyriakou Children’s Hospital, Athens, Greece, 9Helios Klinikum, Berlin, Germany, 10Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, 11Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Cerrahpasa, Turkey, 12Dokuz Eylul University, Izmir, Turkey, 13Aichi Medical University, Nagakute, Japan, 14Children's Hospital Aghia Sophia, Athens, Greece, 15State Pediatric Medical Academy, Saint Petersburg, Russia, 16University of Alabama at Birmingham, Birmingham, 17Universitats-Kinderspital, Zurich, Switzerland, 18National and Kopdistrian University of Athens, Athens, Greece, 19Division of Paediatric Rheumatology and Immunology, University of Zagreb, Zagreb, Croatia, 20Seattle Children's Hospital, Seattle

    Background/Purpose: Macrophage activation syndrome (MAS) is a severe complication of rheumatologic conditions, mainly systemic juvenile idiopathic arthritis (sJIA), and is classified among the secondary forms…
  • Abstract Number: 190 • 2020 Pediatric Rheumatology Symposium

    Outcomes of an Evidence Based Guideline for the Treatment of Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome

    Kacie Hoyt1, Olha Halyabar 2, Joseph Han 3, Siobhan Case 4, Margaret Chang 5, Ezra Cohen 6, Fatma Dedeoglu 5, Mark Gorman 7, Jonathan Hausmann 8, Erin Janssen 2, Pui Lee 9, Jeffrey Lo 5, Mindy Lo 5, Esra Meidan 10, Peter Nigrovic 1, Jordan Roberts 5, Mary Beth Son 1, Robert Sundel 2, Barbara Degar 5, Melissa Hazen 7 and Lauren Henderson 11, 1Boston Children's Hospital, Boston, Massachusetts, 2Children's Hospital/Boston Medical Center, Boston, 3Mount Sinai School of Medicine, New York, 4Brigham and Women's Hospital, Boston, Massachusetts, 5Boston Children's Hospital, Boston, 6, 7Boston, 8Division of Immunology, Boston Children's Hospital; Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 9Boston Children's Hospital, Newton, 10Somerville, 11Boston Children's Hospital, Watertown, Massachusetts

    Background/Purpose: Rapid identification of hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) coupled with a multidisciplinary approach to management is essential to improve patient outcomes.…
  • Abstract Number: 009 • 2020 Pediatric Rheumatology Symposium

    Emapalumab (Anti-Interferon-Gamma Monoclonal Antibody) in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA)

    Fabrizio De Benedetti1, Paul Brogan 2, Claudia Bracaglia 1, Manuela Pardeo 1, Giulia Marucci 1, Emanuela Sacco 1, Despina Eleftheriou 3, Charalampia Papadopoulou 3, Alexei Grom 4, Pierre Quartier 5, Rayfel Schneider 6, Philippe Jacqmin 7, Rikke Frederiksen 8, Maria Ballabio 9 and Cristina de Min 8, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 2UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 3UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Section Head Infection, Immunology, and Rheumatology, London, United Kingdom, 4Cincinnati Children's Hospital Medical Center, Cincinnati, 5Paris-Descartes University, IMAGINE Institute, RAISE reference centre, Pediatric Immuno-Hematology and Rheumatology Unit, Necker hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, 6The Hospital for Sick Children, Toronto, Canada, 7MnS Modelling and Simulation, Dinant, Belgium, 8Swedish Orphan Biovitrum AG (Sobi), Basel, Basel-Stadt, Switzerland, 9Swedish Orphan Biovitrum AG (Sobi), Basel, Switzerland

    Background/Purpose: MAS is a severe complication of rheumatic diseases and occurs most frequently in patients with sJIA. Data from animal models and from observational studies…
  • Abstract Number: 780 • 2019 ACR/ARP Annual Meeting

    Changes in MiR-17-92 Cluster Expression Link Systemic Juvenile Idiopathic Arthritis, Monocyte-to-Macrophage Differentiation, and Interferon Regulation

    Divya Takellapti1, Xiaoling Niu 2, Thuy Do 3 and Grant Schulert 3, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Fudan University, Shanghai, Shanghai, China (People's Republic), 3Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: MicroRNAs (miRNAs) are small noncoding RNAs which post-transcriptionally regulate gene expression. The miR-17-92 cluster is well characterized; its overexpression has been found to serve…
  • Abstract Number: 811 • 2019 ACR/ARP Annual Meeting

    Monomethyl Fumarate as a Novel Therapy for Macrophage Activation Syndrome: Mechanism of Action in an Animal Model

    Chhanda Biswas 1, Thomas Burn 1, Niansheng Chu 1 and Edward Behrens1, 1The Children's Hospital of Philadelphia, Philadelphia

    Background/Purpose: Macrophage activation syndrome (MAS) is a deadly systemic inflammatory condition marked by an increase in enzymes of iron metabolism including ferritin and heme-oxygenase 1…
  • Abstract Number: 813 • 2019 ACR/ARP Annual Meeting

    Monocyte and Macrophage Transcriptional Phenotypes in Systemic Juvenile Idiopathic Arthritis Reveal TRIM8 as a Mediator of IFNγ Hyperresponsiveness and Risk for Macrophage Activation Syndrome

    Grant Schulert1, Thuy Do 1, Sanjeev Dhakal 1, Ndate Fall 2, Mario Medvedovich 3, Sherry Thornton 1, Nathan salomonis 2 and Alexei A. Grom 1, 1Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3University of Cincinnati College of Medicine, Cincinnati, OH

    Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a severe and distinct subtype of childhood arthritis. Children with SJIA are at risk for macrophage activation syndrome…
  • Abstract Number: 916 • 2019 ACR/ARP Annual Meeting

    Development and Initial Validation of the MS Score for Diagnosis of Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis

    Francesca Minoia1, Francesca Bovis 2, Sergio Davì 3, AnnaCarin Horne 4, Michel Fischbach 5, Michael Frosch 6, Adam Huber 7, Marija Jelusic 8, Sujata Sawhney 9, Deborah McCurdy 10, Clovis Artur Silva 11, Donato Rigante 12, Erbil Unsal 13, Nicolino Ruperto 14, Alberto Martini 15, Randy Cron 16 and Angelo Ravelli 15, 1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Lombardia, Italy, 2Università degli Studi di Genova, Genoa, Italy, 3IRCCS Istituto Giannina Gaslini, Genova, Italy, 4Karolinska University Hospital, Stockholm, Sweden, 5Hopital Universitaire Hautepierre, Strasbourg, France, 6School of Medicine Witten/Herdecke University, Datteln, Germany, 7IWK Health Centre, Halifax, NS, Canada, 8University of Zagreb, Zagreb, Croatia, 9Sir Ganga Ram Hospital, New Delhi, India, 10University of California, MDCC 12-430, 10833 Le Conte Ave, Los Angeles, 90095, CA, USA, Los Angeles, 11Childrens’ Institute, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, 12Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 13Dokuz Eylul University, School of Medicie, Izmir, Turkey, 14Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 15IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, 16University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Macrophage activation syndrome (MAS) is the most severe complication of systemic juvenile idiopathic arthritis (sJIA) and its adult equivalent, adult-onset Still’s disease (AOSD).  Because…
  • Abstract Number: 917 • 2019 ACR/ARP Annual Meeting

    Systemic Juvenile Idiopathic Arthritis-Lung Disease: Characterization and Risk Factors

    Grant Schulert1, Shima Yasin 2, Brenna Carey 3, Claudia Chalk 3, Thuy Do 1, Andrew Schapiro 3, Ammar Husami 3, Allen Watts 3, Hermine Brunner 4, Jennifer Huggins 3, Elizabeth Mellins 5, Esi Morgan 3, Tracy Ting 3, Bruce Trapnell 6, Katheryn Wikenheiser-Brokamp 3, Christopher towe 3 and Alexei A. Grom 1, 1Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 5Stanford University, Palo Alto, 6Cincinnati Children's Hospital, Cincinnati

    Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) is associated with a recently recognized albeit poorly defined and characterized lung disease (LD). Our objective is to describe…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology